In a full multivariate analyses (including all parameters mentioned above) of high risk CRC subcohorts (UICC stage III/high tumour budding activity), SATB2 fully retained its prognostic relevance demonstrated in univariate analyses (UICC stage III CRC subcohort: DSS: p = 0.007, hazard ratio: 1.95, Table 3; Bd3-CRCs with a high tumour budding activity DSS: p = 0.01, hazard ratio: 1.67, Table 4; DFS: p = 0.02, Hazard Ratio: 1.79; OS: p = 0.01, hazard ratio: 1.58, data not shown). This evidence concerns the gene SATB2 and neoplasm.